David Hallal is a proven 30-year veteran in the biopharmaceutical industry, having grown and operated several successful biotechnology companies. During his 10-year tenure at Alexion Pharmaceuticals, where he served as Chief Executive Officer, Chief Operating Officer and Chief Commercial Officer, Mr. Hallal led the pipeline expansion from a single-product to multi-product company, resulting in Alexion’s inclusion into the S&P 500. Prior to Alexion, Mr. Hallal spent nearly 20 years at Amgen, Biogen, and Eyetech in executive and senior leadership roles.

Mr. Hallal serves as Chairman and CEO of ElevateBio, an Independent Chairman of Scholar Rock (SRRK) and iTeos Therapeutics, as well as an Independent Director of Seer. He holds a BA in psychology from the University of New Hampshire.